It is still a matter of debate, but it has been described in literature. Would you opt for an OLT for unresectable non-metastatic cholangiocarcinoma?
If you mean hilar cholangiocarcinoma the only answer can be YES. The reported 5-year survival rates after LTx for hilar bile duct cancer (even if considered classically unresectable) are much higher than those obtained with R0-resection in resectable disease. For me the real question is which group of the resectable population will be better to treat with transplantation.
though MAYO university has done it using their own protocol MAYO PROTOCOL as far as in asian countries we are still yet to see a single patient who actually made it, what happens is most of them are not fit or others not able to withstand the protocol
There are a lot of papers coming from US and European centers. The collected report from 12 high-volume US centers showed 65% 5-year survival for patients treated with neoadjuvant CRT followed by LTx:
http://www.ncbi.nlm.nih.gov/pubmed/22504095
Most of European centers also used the same policy. It seems that the availability of donors is the limiting factor for more extensive use of this treatment modality, rather than the concerns about its effectiveness.
There is a study under way in China comparing two treatment methods of unresectable cholangiocarcinoma: with stenting alone, compared with RFA and stenting. The survival differences were statistically significant: http://emcision-2204653.hs-sites.com/endobiliary-rfa-with-without-stenting
- Badges
- Science topic
- Similar topics
- Physical Sciences
- Physical Phenomena
- Luminescence
- Fluorescence